首页> 美国卫生研究院文献>Clinical Microbiology Reviews >Interleukin-12 in infectious diseases.
【2h】

Interleukin-12 in infectious diseases.

机译:白细胞介素12在传染病中。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Interleukin-12 (IL-12) is a potent immunoregulatory cytokine that is crucially involved in a wide range of infectious diseases. In several experimental models of bacterial, parasitic, viral, and fungal infection, endogenous IL-12 is required for early control of infection and for generation and perhaps maintenance of acquired protective immunity, directed by T helper type 1 (Th1) cells and mediated by phagocytes. Although the relative roles of IL-12 and gamma interferon in Th1-cell priming may be to a significant extent pathogen dependent, common to most infections is that IL-12 regulates the magnitude of the gamma interferon response at the initiation of infection, thus potentiating natural resistance, favoring Th1-cell development; and inhibiting Th2 responses. Treatment of animals with IL-12, either alone or as a vaccine adjuvant, has been shown to prevent disease by many of the same infectious agents, by stimulating innate resistance or promoting specific reactivity. Although IL-12 may enhance protective memory responses in vaccination or in combination with antimicrobial chemotherapy, it is yet unclear whether exogenous IL-12 can alter established responses in humans. Continued investigation into the possible application of IL-12 therapy to human infections is warranted by the role of the cytokine in inflammation, immunopathology, and autoimmunity.
机译:白介素12(IL-12)是一种有效的免疫调节细胞因子,与多种传染病至关重要。在细菌,寄生虫,病毒和真菌感染的几种实验模型中,内源性IL-12是感染的早期控制以及T型辅助性1(Th1)细胞指导并由T介导的介导的生成和维持所获得的保护性免疫所必需的。吞噬细胞。尽管IL-12和γ干扰素在Th1细胞启动过程中的相对作用可能在很大程度上取决于病原体,但大多数感染的共同点是IL-12会在感染开始时调节γ干扰素反应的强度,从而增强自然抗性,有利于Th1细胞的发育;并抑制Th2反应。已显示用IL-12单独或作为疫苗佐剂治疗动物,可通过刺激先天性抵抗力或增强特异性反应,通过许多相同的传染原预防疾病。尽管IL-12可以在疫苗接种或与抗微生物化学疗法联用时增强保护性记忆反应,但目前尚不清楚外源IL-12是否可以改变人类已建立的反应。细胞因子在炎症,免疫病理和自身免疫中的作用保证了对IL-12治疗可能应用于人类感染的持续研究。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号